INSC Variant 1: A Potential Drug Target Or Biomarker (G387755)
INSC Variant 1: A Potential Drug Target Or Biomarker
INSC (IN squirrel) is a novel biomarker caused by INSC variant 1, a genetic mutation. The findings suggest that INSC variant 1 may be a potential drug target or biomarker. This article will describe the basic information, characteristics and possible drug targets or biomarkers of INSC variant 1.
Basic Information
INSC variant 1 is a genetic mutation that occurs in the coding region of the INSC gene. The protein encoded by this gene is a glycoprotein also known as an integrin receptor. Glycoproteins are complexes composed of two sugar molecules and protein molecules. They have broad application prospects in the fields of cell signaling, tissue engineering, and regenerative medicine.
feature
INSC variant 1 has the following characteristics:
1. Changes in expression pattern: INSC variant 1 causes changes in the expression pattern of INSC genes. The study found that the INSC variant 1 gene expressed a reduced amount of protein and an increased amount of expressed glycoprotein.
2. Cell adhesion: INSC variant 1 causes the weakening of INSC cell cell adhesion. Cell adhesion is an important process of cell-tissue interaction, which is closely related to processes such as cell proliferation, tissue repair and regeneration.
3. Morphological changes: INSC variant 1 causes changes in the morphological structure of INSC cells. Specifically, INSC variant 1 cells became thinner, longer, more uniform, and had a different shape.
4. Functional studies: Studies have shown that the protein encoded by INSC variant 1 has the effect of inhibiting vascular endothelial growth factor (VEGF). VEGF is an important factor that promotes blood vessel growth and cancer cell invasion. Inhibition of VEGF may have antitumor and antiangiogenic effects.
drug target or biomarker
INSC variant 1 may be a potential drug target or biomarker because it encodes a protein that inhibits vascular endothelial growth factor (VEGF). VEGF is an important factor that promotes blood vessel growth and cancer cell invasion. Inhibition of VEGF may have antitumor and antiangiogenic effects.
In addition, INSC variant 1 may also be a biomarker for assessing disease status and treatment response in patients. For example, by measuring the expression levels of INSC variant 1, patients' disease severity and treatment response can be assessed.
in conclusion
In summary, INSC variant 1 is a potential drug target or biomarker. By inhibiting vascular endothelial growth factor (VEGF), INSC variant 1 may have anti-tumor and anti-angiogenic effects. In addition, INSC variant 1 may also be a biomarker for assessing disease status and treatment response in patients. Therefore, it is important to study the biological and clinical significance of INSC variant 1.
Protein Name: INSC Spindle Orientation Adaptor Protein
Functions: May function as an adapter linking the Par3 complex to the GPSM1/GPSM2 complex (PubMed:16458856). Involved in spindle orientation during mitosis. May regulate cell proliferation and differentiation in the developing nervous system. May play a role in the asymmetric division of fibroblasts and participate in the process of stratification of the squamous epithelium (By similarity)
More Common Targets
INSIG1 | INSIG2 | INSL3 | INSL4 | INSL5 | INSL6 | INSM1 | INSM2 | INSR | INSRR | Insulin-like growth factor | Insulin-like growth factor 2 mRNA binding protein | Insulin-like growth factor 2 mRNA-binding protein 1 (isoform 2) | Insulin-like growth factor-binding protein | INSYN1 | INSYN2A | INSYN2B | Integrator complex | Integrin alpha1beta1 (VLA-1) receptor | Integrin alpha2beta1 (VLA-2) receptor | Integrin alpha2beta3 Receptor | Integrin alpha3beta1 receptor | Integrin alpha4beta1 (VLA-4) receptor | Integrin alpha4beta7 (LPAM-1) receptor | Integrin alpha5beta1 (VLA-5) receptor | Integrin alpha5beta3 receptor | Integrin alpha6beta1 Receptor | Integrin alpha6beta4 receptor | Integrin alpha7beta1 Receptor | Integrin alpha9beta1 receptor | Integrin alphaEbeta7 receptor | Integrin alphaLbeta2 (LFA-1) receptor | Integrin alphaMbeta2 (MAC-1) Receptor | Integrin alphavbeta1 | Integrin alphavbeta3 (vitronectin) receptor | Integrin alphavbeta5 receptor | Integrin alphavbeta6 receptor | Integrin alphavbeta8 Receptor | Integrin Receptor | Integrin-linked kinase | Interferon | Interferon-alpha (IFN-alpha) | Interferon-gamma Receptor | Interleukin 17 | Interleukin 21 receptor complex | Interleukin 23 complex (IL-23) | Interleukin 35 | Interleukin-1 | Interleukin-1 receptor-associated kinase (IRAK) | Interleukin-12 (IL-12) | Interleukin-18 Receptor Complex | Interleukin-27 (IL-27) Complex | Interleukin-39 (IL-39) | Interleukin-7 receptor | Intraflagellar transport complex | Intraflagellar transport complex A | Intraflagellar transport complex B | Intrinsic Tenase Complex | INTS1 | INTS10 | INTS11 | INTS12 | INTS13 | INTS14 | INTS15 | INTS2 | INTS3 | INTS4 | INTS4P1 | INTS4P2 | INTS5 | INTS6 | INTS6L | INTS6L-AS1 | INTS6P1 | INTS7 | INTS8 | INTS9 | INTU | Invariant T Cell Receptor | INVS | Inward Rectifier Potassium Channel | IP6K1 | IP6K2 | IP6K3 | IPCEF1 | IPMK | IPO11 | IPO11-LRRC70 | IPO13 | IPO4 | IPO5 | IPO7 | IPO8 | IPO9 | IPO9-AS1 | IPP | IPPK | IPW | IQCA1